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Abstract
Glucocorticoids (GCs) such as prednisolone are potent immunosuppressive drugs but suffer from severe adverse effects,
including the induction of insulin resistance. Therefore, development of so-called Selective Glucocorticoid Receptor
Modulators (SGRM) is highly desirable. Here we describe a non-steroidal Glucocorticoid Receptor (GR)-selective compound
(Org 214007-0) with a binding affinity to GR similar to that of prednisolone. Structural modelling of the GR-Org 214007-
0 binding site shows disturbance of the loop between helix 11 and helix 12 of GR, confirmed by partial recruitment of the
TIF2-3 peptide. Using various cell lines and primary human cells, we show here that Org 214007-0 acts as a partial GC
agonist, since it repressed inflammatory genes and was less effective in induction of metabolic genes. More importantly, in
vivo studies in mice indicated that Org 214007-0 retained full efficacy in acute inflammation models as well as in a chronic
collagen-induced arthritis (CIA) model. Gene expression profiling of muscle tissue derived from arthritic mice showed
a partial activity of Org 214007-0 at an equi-efficacious dosage of prednisolone, with an increased ratio in repression versus
induction of genes. Finally, in mice Org 214007-0 did not induce elevated fasting glucose nor the shift in glucose/glycogen
balance in the liver seen with an equi-efficacious dose of prednisolone. All together, our data demonstrate that Org 214007-
0 is a novel SGRMs with an improved therapeutic index compared to prednisolone. This class of SGRMs can contribute to
effective anti-inflammatory therapy with a lower risk for metabolic side effects.
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Introduction
Synthetic glucocorticoids (GCs), like prednisolone, are among
the most prescribed anti-inflammatory drugs for diseases like
rheumatoid arthritis, inflammatory bowel disease and asthma.
However, prolonged and/or high dosage GC treatment is
associated with severe side effects such as insulin resistance,
osteoporosis, skeletal muscle wasting, mood disorders and many
others [1,2]. The wide range of side effects is not surprising giving
the essential role of the natural glucocorticoid cortisol in survival.
For example, cortisol has a major role in blood glucose
homeostasis and is essential for induction of stress-coping
mechanisms. Effects of GCs are mediated via the ubiquitously
expressed glucocorticoid receptor (GR), a member of the nuclear
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receptor super family. The small lipophilic GC molecule diffuses
across the plasma membrane and binds to cytoplasmic GR that,
upon binding of its ligand, alters its conformation and translocates
to the nucleus. Within the nucleus, ligand-bound GR acts as
a transcription factor that regulates expression of a set of target
genes directly or indirectly. Direct regulation occurs via binding of
activated GR homodimers to GC-response elements (GRE) in
promoter regions of genes, thereby suppressing or inducing gene
expression, the latter often termed ‘‘transactivation’’ (TA). Indirect
regulation occurs by binding of activated GR to other transcrip-
tion factors, hence facilitating or suppressing the action of these
transcription factors, the latter often referred to as ‘‘transrepres-
sion’’ (TR) [3]. It has long been thought that the anti-
inflammatory activity of GCs was mainly linked to TR activity,
via interference with the two most important pro-inflammatory
transcription factors, i.e., NFkB and AP-1 [4,5]. The induction of
metabolic side effects by GCs was thought to be mainly related to
TA activity via the induction of many genes encoding enzymes
that are active in metabolic pathways like glucose-6-phosphatase
(G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK).
Because of these two clearly separated GC mechanisms of action
it has long been hypothesized that it should be possible to design
a GC molecule with preserved TR actions and reduced TA effects,
resulting in an improved therapeutic index [6,7,8,9]. Selection of
novel selective GR modulators (SGRMs) with dissociating TA
from TR activities in vitro, have so far only resulted in a few
compounds with improved therapeutic profiles in animal models
[6,10,11,12]. To date, proof of concept in man remains to be
obtained.
Due to a better understanding of the molecular interactions
between the ligand-bound GR and its target molecules, awareness
is growing that the concept of dissociation, based solely on TA vs
TR, is too simplistic. For example, the anti-inflammatory activity
of GCs is also partly driven by TA [13,14,15,3,7] In addition,
results from ongoing studies in GRdim mice showed that some TA
activity of GC is still required for the immune suppressive effect in
a mouse model of RA [16]. Furthermore, besides interference with
NFkB and AP-1, GC-bound GR also interacts with other
transcription factors involved in immune responses like IRF-3,
NFAT, STATs, GATA-3, T-bet and CREB [11,17]. Of note,
a recent publication indicates that a large number of genes
involved in GC-induced side effects is regulated via a functional
negative GRE in their promoter region [15]. Furthermore, a series
of studies has shown that even subtle changes in the GR-ligand
may alter conformation of the ligand-receptor complex with
consequences for co-factor recruitment and hence for function of
the receptor [9,18,19,20,21,22,23,24].
Here we describe a novel non-steroidal, low-molecular weight
GR ligand, Org 214007-0, the design of which was based on
interference with the loop between helix 11 and helix 12 at the
ligand-GR binding site. In comparison to prednisolone Org
214007-0 shows an overall improved therapeutic index in vitro as
well as in vivo. Most importantly Org 214007-0 displays sustained
full anti-inflammatory activity in vivo in mice, without adverse
effects on plasma glucose levels and hepatic glucose metabolism.
Results




of which is shown in Figure 1A, has a molecular weight of 430 g/
mole (C24H23N5OS). Synthesis of Org 214007-0 (described in
detail in reference) [25] was based on both structural rationale and
optimization of this class of tetracyclic compounds via molecular
profiling, as will be described below. The structural rationale was
based on GR mutation studies and ligand-based structure-activity
relationships reviewed by Lusher et al [26]. These studies indicate
that the loop between helix-11 and helix-12 of GR represents
a hotspot that is crucial to the agonism/antagonism balance in
GR, amongst others through modification of co-activator binding.
In particular, modified binding of the third LXXLL motif in co-
activators as Steroid Receptor Co-activator (SRC)-1 and Tran-
scriptional Intermediary Factor (TIF)2 by conformational changes
of this loop has been desribed [20,22].
The strategy in the design of Org 214007-0 was therefore to
interfere with this hotspot region, potentially inducing a confor-
mational change of GR that differs from that induced by
prednisolone and modifying co-activator binding. Figure 1B shows
the predicted binding mode of Org 214007-0 modeled in complex
with GR and demonstrates conservation of interactions typical to
steroidal glucocorticoids (Asn564, Gln570, Arg611 and Gln642).
To investigate whether Org 214007-0 in comparison to prednis-
olone indeed caused diminished recruitment of co-activator third
motif LXXLL, a full dose-range of prednisolone and Org 214007-
0 on recruitment of a peptide presenting TIF2 -3 was performed.
The results showed that Org 214007-0, in comparison to
prednisolone, recruited the peptide as a partial agonist, i.e. with
similar potency but with lower efficacy (Figure 2A).
In vitro profiling
Org 214007-0 was found to bind to GR as efficient as
prednisolone (Ki of 2.2 nM vs. 3.8 nM for prednisolone)
(Table 1, row A). For a full molecular profiling of Org 214007-
0 and establishing whether changes in the Org 214007-0-induced
GR conformation would specifically affect the expression of
a selection of GR targetgenes in vitro, the following studies were
performed in which Org 214007-0 was compared to prednisolone.
GR-selectivity of Org 214007-0, either as agonist or antagonist,
was evaluated by testing the compound in CHO cell lines, co-
transfected with one of the human nuclear receptors and their
respective reporter construct. In comparison to prednisolone, Org
214007-0 showed a strong potency but a clearly lower efficacy
(32%, agonistic mode) in the GRE-mediated induction of gene
expression in the human GR transfected cell line (Table 1, row B).
No agonistic activity of Org 214007-0 for other human steroid
receptors was detected. Org 214007-0 only possessed minor
antagonistic activity for the human progestagen (B) and mineral-
ocorticoid receptor, as shown in Table S1 in Text S1. In vivo
activity of Org 214007-0 at therapeutic dose via PR was ruled out
using the rabbit McPhail test, as shown in Table S2 in Text S1. To
investigate whether in comparison to prednisolone the partial GR
agonistic activity of Org 214007-0 would be sustained in cells that
express endogenous GR and that are more relevant to the
metabolic side effects of GCs, the human hepatocytic cell line
HepG2 was used. Instead of focusing on a limited set of genes the
genome-wide effect of both GCs was investigated by microarray
analysis on total mRNA isolated from these cells The genes
regulated by Org 214007-0 represented a subset of the genes
regulated by prednisolone. However, the average maximal efficacy
of induction of gene expression by Org 214007-0, compared to
prednisolone (set at 100%) was 67% (Table 1, row C.) confirming
partial agonistic activity of Org 214007-0 in these cells. For a few
genes, i.e., tyrosine aminotransferase (TAT) and glucose 6-
phosphatase (G6Pase) the partial induction by Org 214007-0 in
comparison to prednisolone was confirmed for a whole dose-range
of the compounds using Q-PCR (Figure S1). The anti-inflamma-
Org 214007-0, a SGRM with Improved TI
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tory activity of Org 214007-0 in comparison to prednisolone was
quantified in a stably human GR transfected cell line (U2OS)
stimulated to elicit an inflammatory response. Org 214007-0 was
shown to inhibit this response with a potency comparable to that
of prednisolone, while its efficacy was somewhat less compared to
prednisolone (81%) (Table 1, row D).
A key next phase in profiling Org 214007-0 against prednis-
olone was to compare both repression and induction of gene
expression within the same cell, which allows for the determination
of a relative therapeutic index (TI) defined as the ratio between %
efficacy by which genes are repressed/% efficacy by which genes
are induced in comparison to prednisolone (set at 1 = 100%/
100%). Org 214007-0 and prednisolone were tested in the human
monocytic THP1 cell line and microarray analyses were
performed to assess both induction of gene expression and
repression of gene expression under an inflammatory condition.
All the genes that were either induced or repressed by Org
214007-0 were also regulated by prednisolone: yet, in all cases the
fold-induction of genes by Org 214007-0 was less and the fold-
repression of genes was equal to or less than that by prednisolone.
Shown in Figure 3A and 3B are the gene sets ranked on basis of
the magnitude of up- and down-regulation by prednisolone
respectively. The top 25 genes from each set were used for further
evaluation in which we calculated a mean fold change for either
the induction or repression of genes by both compounds (see
Figure S2). These calculations show that in this cell system Org
214007-0 shows an average maximal gene induction of 19.5% and
an average maximal gene repression of 48.3% resulting in a 2.5
Figure 1. Structure and predicted binding mode of Org 214007-0. A) The structure of ORG 214007-0. This compound, [(-)-N-(2S,10S,14bS)]-N-
(8-cyano-1,2,3,4,10,14b-hexahydro-10-methyl dibenzo[c,f]pyrido[1,2-a]azepin-2-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamide] has a molecular weight
of 430 g/mole (C24H23N5OS) B) The predicted binding mode of Org 214007-0 modeled in complex with the glucocorticoid receptor and
demonstrating conservation of interactions typical to steroidal glucocorticoids (Gln564, Asn570, Arg611 and Gln642).
doi:10.1371/journal.pone.0048385.g001
Figure 2. Org 214007-0 behaves as a partial agonist in vitro. A) In a co-factor recruitment assay, Org 214007-0, in comparison to
prednisolone, shows potent but partial recruitment of a 0.1 mM peptide presenting TIF2 -3. On the Y-axis average fluorescence counts (+/2 SD) are
shown. EC50 values (%CV) and percentages maximal efficacy (%CV) for Org 214007-0 versus prednisolone were 10 (7.4) nM versus 48 (3.2) nM and 67
(7.1) % vs 100% respectively. B) In THP1 cells Org 214007-0 shows partial induction of FKBP51 protein expression and C) under inflammatory
conditions represses the IL-6 protein expression almost as good as prednisolone does.
doi:10.1371/journal.pone.0048385.g002
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fold improvement of the TI relative to prednisolone (Table 2, row
A). One gene that is induced (FKBP51; Figure 3C) and one gene
that is repressed (IL-6; Figure 3D) are shown as examples. For
a small selection of genes, these differences in expression levels
were confirmed, comparing a whole dose range of Org 214007-
0 and prednisolone by either Q-PCR for FKBP51, GILZ and
DUSP (Figure S3) or by specific AlphaLISAs for FKBP51
(Figure 2B) IL-6 (Figure 2C), MCP-1, and IL-8 (Figure S3).
In order to define in more detail the molecular mechanism that
underlies the differential effects of Org 214007-0 compared to
prednisolone on gene expression, we performed ChIP-Seq analysis
on DNA from the THP-1 cells. Compared to vehicle, the numbers
of clusters found for Org 214007-0 versus prednisolone under the
non-stimulated condition were 2080 vs. 9413, respectively. An
example of these clusters in the FKBP51 gene is shown in
Figure 4B. Under the inflammatory condition, the numbers of
clusters were 2502 vs. 3471. So, under both conditions, Org
214007-0, causes less binding of GR to the DNA than
prednisolone does. Comparison of the set of 2080 putative binding
sites of Org 214007-0 with the 9413 binding sites of prednisolone
showed that 99.5% of the binding sites in the Org 214007-0 set
were also contained within the prednisolone set, indicating that
Org 214007-0 is a genuine GC that does not lead to binding of
GR on sites that are not targeted by prednisolone. This is in close
agreement with the microarray data in which a similar large
overlap was shown between the 2 gene sets. The ratio of the read
count for clusters induced by prednisolone or Org 214007-0 is
shown in Figure 4A as a histogram. Clearly, most clusters have
a ratio greater than 1 (2log ratio larger than 0), indicating that
prednisolone leads to more GR occupancy than Org 214007-
0 does.
Next, effects of Org 214007-0 on the cytokine release by
primary human whole blood cells treated with either LPS or anti-
CD28/PMA were tested. As depicted in Table 2, row D, maximal
efficacies of Org 214007-0 again were partial compared to
prednisolone, resulting in a relative TI of 1.7 (additional data are
shown in Table S3 in Text S1). Potencies of both compounds were
in the same order of magnitude (see IC50’s in Table 2, row D) In
addition, Org 214007-0 and prednisolone were compared in some
of the Biologically Multiplexed Activity Profiling (BioMAP) assays
at BioSeek, Inc. (Burlingame, CA, USA). These assays make use of
different types of primary human cells, in this case coronary artery
smooth muscle cells and neonatal foreskin fibroblasts, in an
inflammatory environment [27,28]. As can be seen in Table 2,
rows E and F, Org 214007-0 showed full efficacies in the two cell
systems, i.e., 98% and 120% repression of MCP-1 and MMP-1,
respectively. Also in these cells, partial induction of protein
expression by Org 214007-0 in comparison to prednisolone was
observed, i.e. 58% for serum amyloid A and 55% for plasminogen
activator inhibitor-1. When all repressed and induced proteins are
taken into account, a relative TI value for Org 214007-0 could be
deduced of 1.7 in coronary artery smooth muscle cells and of 2.2
in neonatal foreskin fiboblasts.
In vivo studies
To evaluate how the in vitro profile of Org 214007-0 would
translate to the in vivo situation with regard to both anti-
inflammatory efficacy and induction of side effects, the compound
was tested head-to-head to prednisolone in several in vivo models.
Since pharmacokinetic studies in mice showed good oral bio-
availability of Org 214007-0 and prednisolone (shown in Table S4
in Text S1), both compounds were dosed orally in all preclinical
mouse models. Firstly, Org 214007-0 was tested in an acute
inflammation model for its potency to inhibit the LPS-induced
raise in serum TNFa. As can be seen in Figure 5A, the potency of
Org 214007-0 in this model was stronger than that of prednisolone
(ED50 0.5 mg/kg vs. 1 mg/kg). Surprisingly, and in contrast to its
in vitro repression efficacy on LPS-induced TNFa, the maximal
efficacy of Org 214007-0 in this model was as good as that of
prednisolone, reaching a 90% inhibition of the LPS-induced
TNFa release. Administration of GR antagonist RU486 (mife-
pristone) to the mice just prior to oral treatment with either Org
214007-0 or prednisolone fully antagonized this inhibition (data
for Org 214007-0 in Figure S4), confirming that inhibition of the
TNFa response was indeed mediated via GR. The effect of Org
214007-0 was also tested in a T-cell-driven inflammation model
using anti-CD3-induced IL-2 release as readout. As can be seen in
Figure 5B, Org 214007-0 dose-dependently reduced the anti-CD3
induced IL-2 serum levels with a similar efficacy as prednisolone
(75% inhibition) but with a stronger potency than prednisolone
(ED50 approximately 0.3 mg/kg vs. ca. 10 mg/kg). This again
demonstrates that, although Org 214007-0 behaves as a true
partial GR agonist in vitro, it shows anti-inflammatory activity as
good as prednisolone in vivo.
Table 1. Summary of in vitro studies.
Cells/Assay Stimulus Read-out Parameter Unit Pred Org
A GR-binding - competitive binding Ki nM 3.8 (60.8) 2.2 (61.3)
B CHO – ind - MMTV-luc EC50 nM 26.2 (67.5) 5.1 (61.6)
Max. eff. % 100 32 (68.1)
C HepG2 – ind - micro-array Max eff. % 100 67
D U2OS – rep IFNc/TNFa MCP-1 IC50 nM 0.74 (62.3) 0.36 (60.19)
Max. eff. % 100 (69.6) 81 (616)
Prednisolone (Pred) and Org 214007-0 (Org) were tested in different in vitro studies. A) GR binding: binding to recombinant human glucocorticoid receptor (GR) assessed
by a fluorescence polarization competitor binding assay. Ki = inhibition constant or concentration of compound in the competitive binding assay which would occupy
50% of GR if no ligand was present. B) CHO – ind: Induction of gene expression measured in CHO cells stably co-transfected with human GR and a MMTV promoter –
luciferase construct. C) HepG2 – ind: Induction of gene expression measured by microarray analysis of mRNA isolated from HepG2 cells incubated with either 1 mM
prednisolone or 1 mM Org 214007-0. D) U2OS – rep: Repression of gene expression in U2OS cells overexpressing human GR. INFc/TNFa – MCP-1 = IFNc (100 ng/ml)/
TNFa (50 ng/ml) induced MCP-1 release.
IC50 or EC50 values represent the mean concentration of compound (6SD) required to resp. inhibit or effect the response to 50%. Maximal efficacy (Max. eff.) is
expressed as the mean relative maximal effect (6SD) compared to the maximal effect by prednisolone (set at 100%). All assays (except for the micro array experiments)
are performed at least two times.
doi:10.1371/journal.pone.0048385.t001
Org 214007-0, a SGRM with Improved TI
PLOS ONE | www.plosone.org 4 November 2012 | Volume 7 | Issue 11 | e48385
We next tested the efficacy of the compound in a more relevant
chronic disease model in which the classical GCs have proven
efficacy. The murine collagen-induced arthritis (CIA) model is
a well-accepted model of human rheumatoid arthritis, encom-
passing inflammation of synovial joints, destruction of cartilage
and bone erosion. Org 214007-0 and prednisolone were dosed
orally (once daily 3 weeks) in a therapeutic manner, i.e., treatment
started when disease was established. Both prednisolone and Org
214007-0 caused a dose-dependent reduction of the disease score
(Figure 6A). Org 214007-0 was found to be about 3-fold more
potent than prednisolone in this model, leading to a total
suppression of the disease symptoms at a dose of 1.5 mg/kg/
day. Besides the clinical score of the paws, the two highest doses of
Org 214007-0 (0.5 and 1.5 mg/kg/day) also showed a significant
reduction in bone damage as determined by X-ray on knees and
paws at the end of the study (Figure 6B), indicating a reduction of
disease progression. Finally, histopathologic examination of the
inflamed knee joints also showed a significant reduction of
inflammatory infiltrates, cartilage destruction and bone apposition
in mice treated with the two highest doses of Org 214007-
0 (Figure S5). Altogether these results demonstrate that the anti-
inflammatory in vivo efficacy of Org 214007-0 is as good as or even
better than that of prednisolone.
In the same chronic disease model we wanted to test whether
the partial activity of Org 214007-0 on induction of gene
expression and its improved TI, as observed in vitro, would be
sustained in vivo. Evaluation of the gene expression profiles induced
by prednisolone in different tissues and at different time points
after the last dosing of compound in a CIA experiment indicated
that muscle tissue collected 2.5 hours after dosing provided
representative and robust gene expression data. Therefore, muscle
tissue was collected from arthritic mice that were treated for
3 weeks with either vehicle only or with dosages of Org 214007-
0 and prednisolone that were equally effective in inhibiting
arthritis. Besides these groups of mice, one group of healthy mice
(sham-immunized and vehicle-treated) was included. Collected
tissue was used to isolate mRNA for microarray analysis. The top
25 genes (represented by the probes on the chip) that were at least
2-fold up-regulated by either Org 214007-0 or prednisolone in
comparison to vehicle treated mice are shown in Figure 3E Among
these genes are, a.o., FoxO1 and bona fide GR target genes like
Fkbp51 and Per-2 (the latter shown as an example in Figure 3G).
Genes that were at least 2-fold up-regulated by disease induction
(vehicle-treated arthritic vs. vehicle-treated healthy mice) and that
were down-regulated at least 2-fold by either Org 214007-0 or
prednisolone are shown in Figure 3F. Among the genes are some
well-known inflammatory markers as S100A8, S100A9 and Ccl8,
the latter shown as an example in Figure 3H. The fold induction of
gene expression by Org 214007-0 was always lower than that
caused by prednisolone, whereas fold repression of gene expression
was more or less equal for Org 214007-0 and prednisolone. We
also calculated a mean fold change for all induced and repressed
genes by both compounds derived from this microarray. Based on
these calculations Org 214007-0, relative to prednisolone, shows
Figure 3. Org 214007-0 has a relatively lower impact on induction than on respression of genes. Fold changes for the top 25 genes
either induced (A) or repressed (B) by 1 mM prednisolone and 1 mM Org 214007-0 in THP-1 cells. NB. Scales are in 2log. Example of an induced gene,
FK506 binding protein 51 (FKBP51) (C) and a repressed gene, interleukin 6 (IL-6) (D) in comparison to the vehicle control under either non-stimulated
or stimulated (IFNc/TNFa) condition. Fold changes for the top 25 genes either induced (E) or repressed (F) by 1.5 mg/kg prednisolone and 0.3 mg/kg
Org 214007-0 in muscle tissue from arthritic mice. NB. Scales are in 2log. Example of an induced gene (Per-2) (G) and a repressed gene (Ccl8) (H) in
comparison to vehicle treated arthritic mice and vehicle treated healthy mice.
doi:10.1371/journal.pone.0048385.g003
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an average maximal gene induction of 25.7% and an average
maximal gene repression of 87.7%. In other words, also in vivo Org
214007-0 shows a relatively low effect on induction of gene
expression compared to prednisolone at dosages that are equally
effective in suppression of arthritis leading to a relative TI of 3.4
(Table 2, row G).
Finally, we assessed whether Org 214007-0 indeed has a favor-
able TI with respect to its (side-) effects on glucose metabolism.
Mice treated daily with prednisolone for 28 days showed, in
comparison to vehicle treated mice, significantly elevated fasting
blood glucose levels (p,0.01) from day 8 onwards. Interestingly,
in mice treated with equipotent doses of Org 214007-0 fasting
blood glucose levels were not affected (Figure 7).
To evaluate the effects of the compound on hepatic glucose
metabolism, a mass isotopomer distribution analysis (MIDA)
approach was performed. Mice were dosed for 7 days with Org
214007-0 (1.5 mg/kg) or prednisolone (10 mg/kg) or vehicle only.
Daily oral treatment with these dosages of Org 214007-0 and
prednisolone result in more or less equal molar total exposure
levels of both compounds and in equal inhibition of arthritis in the
CIA model as shown previously. Also in this study, the fasting
blood glucose levels in mice treated with prednisolone were
significantly elevated compared to vehicle-treated mice (p,0.05),
Table 2. Summary of studies to define the therapeutic index (TI) of Org 214007-0.
Cells/Assay Stim Read Param Unit Pred Org TIrel
A THP-1 – rep - m.a. Max. eff. % 100 48.3
– ind I/T m.a. Max. eff, % 100 18.9 2.5
B THP-1 – rep I/T MCP-1 IC50 nM 69.9 (630.4) 23.5 (69.3)
Max. eff. % 100 44 (68)
IL-6 IC50 nM 34.1 (66.6) 9.3 (62.1)
Max. eff. % 100 78 (69)
IL-8 IC50 nM 36.9 (611.3) 11.0 (63.1)
Max. eff. % 100 74 (610)
C THP-1 – ind - FKBP51 EC50 nM 65.8 (622.4) 8.0 (65.3) 2.0
Max. eff. % 100 42 (68)
GILZ EC50 nM 60.2 (619.6) 13.7 (611.8)
Max. eff. % 100 13 (65)
DUSP1 EC50 nM 67.4 (68.4) 6.4 (64.1)
Max. eff. % 100 41 (66)
D hWB – rep LPS TNFa IC50 nM 27 (65.7) 50 (619)
Max. eff. % 100 68 (68.7)
P/28 IL-5 IC50 nM 6.76 (61.5) 14.45 (63.2)
Max. eff. % 100 64 (611)
– ind P/28 G-CSF EC50 nM 67.61 (63.8) 186.2 (663) 1.7
Max. eff. % 100 39 (67.8)
E CASM3C – rep 1/I/T MCP-1 Max. eff. % 100 98
– ind - SAA Max. eff. % 100 58 1.7
F HDF3CGF – rep 1/I/T MMP-1 Max. eff. % 100 120
– ind - PAI-1 Max. eff. % 100 55 2.2
G CIA mus. – rep m.a. Max. eff. % 100 87.7
– ind m.a. Max. eff. % 100 25.7 3.4
A) THP-1: Microarray (m.a.) analysis of mRNA isolated from THP-1 cells incubated for 6 hours with either 1 mM prednisolone or 1 mM Org 214007-0 without (ind) or with
IFNc (220 ng/ml)/TNFa (374 ng/ml) ( = I/T), (rep) The mean percentage repression or induction of genes compared to that by prednisolone (set at 100%) is indicated. B)
THP-1 – rep: Repression of gene expression in THP-1 cells. I/T – MCP-1, IL-6, IL-8 = TNFa (60 ng/ml)/IFNc (40 ng/ml) induced MCP-1, IL-6 or IL-8 release. C) THP-1 – ind:
Induction of FK506 binding protein 51 (FKBP51), glucocorticoid induced leucine zipper (GILZ) and dual specificity phosphatase 1 (DUSP1) in THP-1 cells. D) hWB – rep:
Inhibition of LPS-induced (LPS) TNFa release or PMA/anti-CD28 (P/28) induced IL-5 release by primary human whole blood cells and hWB – ind: enhancement of PMA/
anti-CD28/compound (P/28) induced G-CSF release by primary human whole blood cells. E) CASM3C – rep: Inhibition of MCP-1 release of coronary artery smooth muscle
cells ( = CASM3C) stimulated with a cytokine mixture of IL-1b (1 ng/ml), IFNc (100 ng/ml) and TFNa (5 ng/ml) ( = 1/I/T) by 1 mM prednisolone or 1 mM Org 214007-0.
CASM3C – ind: Induction of serum amyloid A (SAA) of the cells mentioned above by 1 mM prednisolone or 1 M Org 214007-0. F) HDF3CGF – rep: inhibition of matrix
metalloproteinase (MMP-1) release of human neonatal foreskin fibroblasts stimulated with the cytokine mixture mentioned above plus required growth factors
( =HDF3CGF). HDF3CGF – ind: Activation of plasminogen activator inhibitor-1 (PAI-1) by cells mentioned above by 1 mM prednisolone or 1 mM Org 214007-0. G) CIA mus.:
Microarray (m.a.) analysis of mRNA isolated from muscle cells isolated at day 21, 2.5 hours after the final oral administration of either 1.5 mg/kg prednisolone or 0.3 mg/
kg Org 214007-0 in the mouse CIA experiment. The mean percentage repression (rep) or induction (ind) of genes compared to that by prednisolone (set at 100%) is
indicated.
IC50 or EC50 values represent the mean concentration of compound (6SD) required to resp. inhibit or effect the response to 50%. Maximal efficacy (Max. eff.) is
expressed as the mean relative maximal effect (6SD) compared to the maximal effect by prednisolone (set at 100%). A relative therapeutic index (TIrel) is calculated by
the ratio of (the mean) % maximal efficacy in repression and (the mean) % maximal efficacy in induction of genes by Org 214007, where that of prednisolone is set at 1
(100%/100%). All assays (except for the microarray experiments) are performed at least two times.
doi:10.1371/journal.pone.0048385.t002
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while Org 214007-0 did not affect fasting blood glucose level
(Figure S6). The hepatic flux rates calculated from the MIDA
results are shown in Figure 8. The glucokinase and glycogen
synthase flux rates were significantly decreased by prednisolone
whereas Org 214007-0 had no significant effects. These differences
in flux rates resulted in differences in glucose and glycogen
balances as shown in Figure 9. Since prednisolone treatment
caused no change in the gluconeogenic flux (from pyruvate to
glucose-6-phosphate) (Figure 8) nor in the blood glucose metabolic
clearance rate (Figure 9), the effect of prednisolone on the
glucokinase and glycogen synthase flux rates may explain the
increase in fasting glucose levels in prednisolone-treated mice. Org
214007-0 did not alter these balances, confirming a significantly
different mode of action of glucose metabolism in comparison to
prednisolone.
Taken together, the in vitro partial GR agonistic profile of Org
214007-0 translates in vivo into a full anti-inflammatory compound
with less adverse effects on glucose metabolism in mice. Org
214007-0 therefore represents a new class of SGRMs with an
improved therapeutic index in comparison to prednisolone. This
class of compounds is highly interesting for further development
towards improved oral SGRMs for clinical use.
Discussion
About two decades ago, the concept of a ‘‘dissociating
glucocorticoid’’ was defined, based on the discovery of the two
different mechanisms of glucocorticoids action: transrepression vs
transactivation. This concept was enforced by the finding that
DNA-binding of the GR-ligand complex was not required for
transrepression [29,5]. Since then, drug discovery programmes
have been initiated on dissociating glucocorticoids (nowadays often
referred to as SGRMs), resulting in the development of a number
of compounds that indeed show improved TR/TA ratio in vitro
(reviewed in reference) [11]. However, only a limited number of
compounds also show a dissociating profile in vivo when tested in
preclinical animal models. The hypothesis that an improved TR/
TA ratio is beneficial in the clinic still awaits its proof of concept in
man. In addition it is now evident that the simple concept of TR
versus TA activity requires revision based on new insights in the
complexity of the mechanisms of GC action. Some TA activity still
seems to be required for the anti-inflammatory action of GCs
[3,7,13,14,15], whereas some side effects of GCs are thought to be
driven by transrepression [30]. An exception to this rule seems to
be observed with the plant-derived compound CpdA that shows
characteristics of a full dissociating GC, lacking any TA activity
[31]. However, the mechanism of action of this compound seems
to differ from a true GC agonist or antagonist, preventing GR-
dimer formation and GR-DNA binding [32].
In this paper we provide an extended in vitro characterization
combined with specific in vivo data on a SGRM that belongs to
a new chemical class of non-steroidal low molecular weight
compounds, i.e., Org 214007-0. Org 214007-0 binds with high
affinity to GR, comparably to prednisolone. In vitro, Org 214007-
0 behaved as a partial GR-selective agonist with a potency
comparable to that of prednisolone. The maximal efficacy on
induction of gene expression by Org 214007-0, in comparison to
prednisolone, appeared to be partial. The maximal efficacy on
repression of inflammatory responses by Org 214007-0 was also
partial but more close to that of prednisolone, resulting in an
improved relative therapeutic index (TI) for Org 214007-0 of
about 2. The typical in vitro profile of Org 214007-0 was confirmed
in several cell lines (HepG2, THP-1) for the total array of GC
modulated genes. In addition, this unique profile of Org 214007-
0 was confirmed in several types of human primary cells under
different pro-inflammatory conditions.
Although Org 214007-0 binds GR with the same affinity as
prednisolone, the conformation of the GR-Org 214007-0 complex
leads to a lower binding affinity to the DNA GR-binding sites in
comparison to the GR-prednisolone complex, as was shown by
Figure 4. Org 214007-0 leads to relatively less GR occupancy. A) Ratio of the read count for clusters induced by 1 mM prednisolone or 1 mM
Org 214007-0 in a ChIP-Seq analysis. If Org 214007-0 and prednisolone would induce an equal number of reads, the histogram would be centered on
Log0, indicated by the dotted line. There is a clear shift to the right from this line (P-value (mean = 0) ,0.000001), indicating that prednisolone leads
to more GR occupancy than Org 214007-0. B) Example profile of the tag clusters in the GR response gene FKBP51. Multiple binding sites are found
within this gene, each showing denser clusters after treatment with 1 mM prednisolone than after treatment with 1 mM Org 214007-0. The inset
highlights an intronic region at 87 kb downstream of the transcription start site. This region that was identified by Paakinaho et al. (2010) [54], as
a major intronic enhancer in human A459 lung cancer cells and was shown to be occupied by GR after treatment with the GR ligand dexamethasone.
doi:10.1371/journal.pone.0048385.g004
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a ChIP-Seq study. These data are in agreement with the partial
activity of Org 214007-0 on gene induction. Modeling the
binding-mode of Org 214007-0 to GR suggests that the molecular
basis for the compounds’ partial agonism involves disturbance of
the loop region between helix-11 and helix-12 rather than a direct
clash with helix-12 itself. The importance of this loop region in
mediating agonism and antagonism for GR has recently been
reviewed [26]. Since co-modulator binding depends on the
position of this helix, this will probably affect recruitment of co-
activators and thereby gene induction activity [22,33]. Recruit-
ment of peptide TIF2-3, previously described to be affected by this
region [20,22] was indeed shown to be partial with Org 214007-
0 bound GR.
The in vivo activity of Org 214007-0 was tested in several mouse
models. Two acute inflammation models demonstrated the anti-
inflammatory activity of Org 214007-0 at the level of both
monocytic cells (LPS-induced TNFa model) and T cells (anti-
CD3-induced IL-2 model). Strikingly, Org 214007-0 was found to
behave as a potent and full GR agonistic anti-inflammatory agent
in these models. Even more importantly, this strong potency and
full anti-inflammatory efficacy was sustained in a chronic disease
model, i.e., the CIA model. Microarray analysis on muscle RNA
from these mice showed that the efficacy in suppression of the CIA
disease score was in line with a reduction of disease-related or pro-
inflammatory genes like TLR4 ligand S100A8/S100A9 [34] and
monocyte chemotactive protein-2 (chemokine[C-C]-ligand 8 or
CCL8) [35]. More importantly, the partial activity of Org 214007-
0 on gene induction, as observed in vitro, was sustained in the
muscle in the CIA model, since the GR-dependent induction of
genes was always lower upon Org 214007-0 treatment compared
to prednisolone. A large part of the induced genes are well-known
GR-regulated genes like FKBP51, FoxO1, phenylethanolamine-
N-methyltransferase (PNMT), Ddit4 (or REDD1), Lcn2 (or
Lipocalin 2) and Per-2 [7,36]. Interestingly, Fox01 was shown to
Figure 5. Org 214007-0 is equally effective as prednisolone in
acute inflammation mouse models. A) Inhibition of acute
inflammation in the LPS-induced TNFa mouse model. Mean percentage
inhibition (of each group of n = 8) (6 SEM) of the LPS-induced TNFa
release by the vehicle treated group is shown (no TNFa is detectable
without LPS injection). ** = significantly different from placebo
(p,0.01; ANOVA-test). B) Inhibition of acute T cell-driven inflammation
in the anti-CD3-induced IL-2 mouse model. Org 214007-0 shows a more
potent activity than prednisolone in this model. Mean percentage
inhibition (of each group of n = 2) (6 SEM) of the anti-CD3-induced IL-2
release relative to a positive control group (treated with 10 mg/kg
A420983, a pan-SRC inhibitor) (set at 100%) is shown (no IL-2 is
detectable without anti-CD3 injection). ** = significantly different from
placebo (p,0.01; ANOVA-test).
doi:10.1371/journal.pone.0048385.g005
Figure 6. Org 214007-0 is equally effective as prednisolone in
the mouse CIA model. A) Inhibition of arthritis in the CIA model.
Mean clinical score of each group (n = 12), shown as area under the
curve (AUC) of the arthritis score monitored every other day during
3 weeks, corrected for baseline, is indicated (6 SEM). ** = significantly
different from placebo (p,0.01; ANOVA-test). B) Reduction of bone
destruction in the CIA model as measured by X-ray. Mean radiological
score (sum of the X-ray scores of left and right hindpaws and knees) of
each group of mice (n = 12) at the end of the CIA experiment is
indicated (6 SEM). ** = significantly different from placebo (p,0.01;
ANOVA-test).
doi:10.1371/journal.pone.0048385.g006
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play a role in muscle atrophy, one of the main unwanted side
effects of chronic GC-treatment. However, Waddell et al [37]
show that Fox01 effects on muscle are mediated through direct
induction of MuRF1 expression, whose promoter contains both
a GRE and a Fox01-binding element. Despite upregulation of
Fox01, MuRF1 was not regulated in our study in muscle of either
prednisolone or Org 214007-0-treated mice. Further studies are
needed to clarify whether our present finding really represent
a discrepancy with existing literature or whether the different
experimental conditions like different kinetics of mRNA expres-
sion give rise to this apparent discrepancy. Moreover, it will be of
great interest to do dedicated studies on muscle wasting to try to
link the gene-expression profiles of Org 214007-0 and predniso-
lone to clinical consequences on muscle mass. Another interesting
gene is Per-2, which belongs to the class of circadian clock genes
and has recently been described as a primary GR target gene
involved in glucose homeostasis [38]. It is tempting to speculate
that a less pronounced induction of Per-2 by Org 214007-
0 compared to an equi-efficacious dose of prednisolone contributes
to a better metabolic side effect profile of Org 214007-0. However,
a functional metabolic side effect profile could not be derived from
our CIA model, since we have not seen any induction of either
glucose or insulin at a dose of 1.5 mg/kg/day prednisolone in our
CIA experiments. Other groups have described increased fasting
glucose or insulin levels in mice treated with prednisolone in acute
inflammation models [6,39] and in a chronic disease model [40].
Riether et al. [40] showed that 30 mg/kg prednisolone induced
significantly elevated serum insulin levels in a mouse CIA
Figure 7. Org 214007-0 induces less elevated fasting glucose levels. Mice (n = 8 per group) are not treated (Control) or treated po, once
daily, for 28 days with either vehicle only, prednisolone 0.5 mg/kg/day or 10 mg/kg/day or Org 214007-0 0.17 mg/kg/day or 1.5 mg/kg/day. Both the
two lowest doses of each compound are equi-efficacious in suppression of CIA as well as the two highest doses. Blood glucose levels (mean 6 SEM)
were measured at day 8, 15, 22 and 29, after 9 hours of fasting. * p,0.05, ** p,0.01, *** p,0.001: significantly different (Student’s t-test) from vehicle
treated group.
doi:10.1371/journal.pone.0048385.g007
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experiment. However, the dose of prednisolone used by Riether
et al. was much higher than the dose (1.5 mg/kg/day) that is fully
efficacious in our CIA model. To gain direct insight in potentially
disqualifying side effects of Org 214007-0 on glucose metabolism,
we have carefully evaluated its effect on glucose metabolism in the
liver by a mass isotopomer distribution analysis (MIDA) approach.
Prior studies that were performed to gain insight in the effects of
prednisolone on glucose metabolism in mice, showed that the
MIDA approach was able to specifically quantify the actions of
prednisolone on hepatic glucose metabolism [41]. Other tests,
such as ipGTT and ipITT, have therefore not been performed
with Org 214007-0 as these would have no additional value.
MIDA has also successfully been applied to study glucose
metabolism in humans [42] and was adapted for use in mice
[43]. Using this method it was found that prednisolone admin-
istration of 10 mg/kg/day for 7 days significantly reduced
glycogen storage in the liver by reducing glucokinase and glycogen
synthase fluxes, while a dose of Org 214007-0 that was equi-
efficacious in reducing arthritis did not. Surprisingly, hepatic
gluconeogenesis was not affected by prednisolone treatment while
the commonly accepted idea is that GCs stimulate gluconeogenesis
via induction of genes like PEPCK and G6Pase. However,
induction of these gluconeogenic genes appears to represent an
acute effect of GCs. Studies on glucose metabolism after a more
chronic GC treatment in man [44,45,46] or mice [47] also showed
a lack of effect on hepatic gluconeogenesis and rather point at an
Figure 8. Org 214007-0 does not effect rates of hepatic enzyme fluxes. Mass Isotopomer Distribution Analysis (MIDA), as described in detail
in Materials and Methods, was performed in mice treated p.o., once daily, for 7 days with either vehicle, prednisolone (10 mg/kg) or Org 214007-
0 (1.5 mg/kg). These doses of each compound are equi-efficacious in suppression of CIA. Neither the glucose-6-phosphatase flux (A) nor the glycogen
phosphorylase flux (B) were affected by treatment with prednisolone or Org 214007-0. The glucokinase flux rate (C) was not changed by Org 214007-
0, but significantly differed from the effect by prednisolone (##: p = 0.01 vs prednisolone). The glycogen synthase flux rate (D) was significantly
decreased by prednisolone (**: p = 0.005 vs vehicle), whereas Org 214007-0 had no significant effect on this flux, but differed significantly from
prednisolone (##: p = 0.002 vs prednisolone). Neither Org 214007-0 nor prednisolone, at equi-efficacious dosages, effects the gluconeogenic flux (de
novo synthesis of glucose-6-phophate) (E).
doi:10.1371/journal.pone.0048385.g008
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effect on glucose disposal. Due to limitation of the volume of blood
taken during the MIDA experiments plasma insulin levels could
not be determined. However, earlier studies have revealed that
chronic prednisolone treatment induces a state of reduced hepatic
insulin sensitivity and a ‘fasting-like phenotype’ in chow-fed mice
[47]. Furthermore, in mice fed with a high fat diet the
prednisolone-induced hyperglycemia and hyperinsulinemia was
aggravated [41]. So, in contrast to prednisolone, Org 214007-0 did
not have any impact on in vivo glucose metabolism in the mouse,
since no effects on fasting blood glucose levels or on hepatic
glucose metabolism were found.
It will be of great interest to further detail effects of Org 214007-
0 versus prednisolone for its efficacy in other therapeutic disease
models but especially also for its adverse effects, e.g. induction of
osteoporosis, diabetes, muscle wasting, and effects on CNS. We
consider Org 214007-0 a perfect tool compound to study the
pharmacological consequence of dissociating transrepression from
transactivation on the therapeutic index of these GCs looking at all
of these well known adverse effects. It should be noted, that not for
all adverse effects a clear improved therapeutic index can be
expected. For instance for bone, it was found that GC-induced
osteoporosis in GR-dimer deficient mice is dependent on
transrepression rather than transactivation [30].
Thus, Org 214007-0, is a non-steroidal SGRM, with a poten-
tially improved therapeutic index compared to prednisolone.
Progress in further preclinical and clinical studies of this new class
of SGRMs could lead to a better understanding of the
consequences of GC-mediated transrepression and transcativation
for the therapeutic index of GCs and to future availability of
improved GCs.
Materials and Methods
Glucocorticoid receptor binding assay
The glucocorticoid receptor (GR) fluorescence polarisation (FP)
binding assay was performed using the commercially available kit
from Panvera (Glucocorticoid receptor competitor assay, Green
Cat# P2816). (for more detailed information see Supportive
Information) (SI text).
Structural modeling
The binding mode of Org 214007-0 in complex with the GR-
LBD was predicted using the flexible docking method Fleksy [48]
and images generated using Pymol (The PyMOL Molecular
Graphics System, Schro¨dinger, LLC.).
Co-factor-peptide recruitment assay
E. coli produced His-GR-LBD (F602S mutated) at 10 nM (final
concentration) plus 0.032 nM to 10 mM GC compound (final
concentration range) were incubated in 20 mL/well in white
OptiPlates (in duplo) for 3 hours at 4uC. Hereafter, peptide,
representing Transcriptional Intermediary Factor 2 – LXXLL
motif 3 (TIF2-3) at 100 nM (final concentration), streptavidin-
APC (8 nM, final concentration) and anti-His-Eu (1.25 nM final
concentration) were added to a total volume of 50 mL/well and
incubation at 4uC was continued for another 20 hours. Fluores-
cence was measured using Tecan Infinite M1000 and data were
analysed by GraphPad Prism.
Assay in U2OS cells
To determine the repressive activity of GR ligands, cell line
U2OS GR.G9, the human osteoblastic cell line U2OS, stably
transfected with human GR, was used. Cells (104 cells/well) were
incubated in 384-wells plates, in the presence of 50 ng/ml TNFa
Figure 9. Org 214007-0 does not cause a shift in the liver glucose/glycogen balance. As determined in MIDA (details in legend Figure 8),
the glucose balance (A), which represents the difference between the glucose-6-phophatase and glucokinase flux, is not affected by Org 214007-
0 treatment but is significantly changed by the prednisolone treated group (*: p = 0.046 vs vehicle.; ##: p = 0.004 vs prednisolone). The glycogen
balance (B), representing the difference between the glycogen synthase and glycogen phophorylase flux, is not effected by Org 214007-0 treatment
but is significantly changed by the prednisolone treated group (*: p = 0.024 vs vehicle; ##: p = 0.005 vs prednisolone). Neither Org 214007-0 nor
prednisolone, at equi-efficacious dosages, effects the metabolic clearance rate of blood glucose (C).
doi:10.1371/journal.pone.0048385.g009
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(R&D systems)/100 ng/ml IFNc (Peprotech) and compound, for
18 hours. Hereafter, a mixture of two different antibodies to
hMCP-1, one Eu-labeled and one APC-labeled, were added. One
hour later the time-resolved fluorometric resonance energy
transfer (TR-FRET) signal was measured. (for more detailed
information see Supportive Information) (SI text).
Assay in CHO cells
For monitoring both human steroid receptor agonistic as well as
antagonistic activity of compounds, Chinese hamster ovary (CHO)
K1 cells stably co-transfected with the specific human steroid
receptor and its respective reporter construct were used (as
previously described) [49].
For human glucocorticoid receptor (GR)-specific activity CHO-
GR B4.8 cells containing both recombinant human GR as well as
a reporter construct consisting of the mouse mammary tumor virus
(MMTV) promotor and the luciferase reporter gene, were used.
Compound was incubated alone (in the agonistic setup) or with
50 nM dexamethasone (in the antagonistic setup) overnight.
Hereafter, 200 ml medium was removed and 50 ml luciferine
substrate solution from the LucLite luminescence kit (Packard,
Meriden, USA) was added. After 10 minutes luminescence of each
sample was counted and percentage maximal agonistic efficacy
was related to the maximal efficacy of prednisolone. Percentage
maximal antagonistic efficacy was related to the maximal
antagonistic efficacy of reference GR antagonist Org 34116.
Similar procedures were followed for the other human steroid
receptor assays (for more detailed information see Supportive
Information) (SI text).
Gene expression profiling in HepG2 cells
HepG2-8/97-WS.5 cells, deprived from serum for 18 hours,
were stimulated with glucocorticoid and 0.5 mM cAMP for
6 hours. RNA was isolated and used for double stranded cDNA
synthesis using the One-Cycle Target Labeling Kit (Affymetrix
Santa Clara, CA). This cDNA was used as a template for the
preparation of biotin-labeled cRNA using the GeneChip IVT
Labeling Kit (Affymetrix Santa Clara, CA). Biotin-labeled cRNA
was fragmented and hybridized at 45uC for 16–17 hours to the
Human Genome U133A 2.0 Array or the Human Genome U133
Plus 2.0 Array (Affymetrix, Santa Clara, CA). (for more detailed
information see Supportive Information) (SI text). Arrays were
stained with phycoerythrin-streptavidin conjugate (Molecular
Probes, Eugene, OR), and the signals were amplified by staining
the array with biotin-labeled anti-streptavidin antibody (Vector
Laboratories, Burlingame, CA) followed by phycoerythrin-strep-
tavidin. The arrays were laser scanned with an GeneChip Scanner
3000 6G (Affymetrix, Santa Clara, CA) according to the
manufacturer’s instructions. Data was saved as raw image file
and quantified using GCOS (Affymetrix). Genes with a fold
change of .2 and a p-value of ,0.05 (after correction for multiple
testing) were selected. The mean fold induction by prednisolone of
these genes was compared with the mean fold induction of these
genes by Org 214007-0 (more detailed information in Supportive
Information) (SI text).
Gene expression profiling in THP-1 cells
THP-1 cells were incubated with glucocorticoid in the presence
of either DMSO (control) or IFNc/TNFa (220 ng/ml/375 ng/
ml). After 6 hours total RNA was isolated and further processed
for microarray hybridization as described for the HepG2 cells.
The data from all microarray experiments have been deposited in
the NCBI Gene Expression Omnibus (GEO) under accession
number (identifier will be included in proof). A therapeutic index
for Org 214007-0 was calculated based on the difference in the
ratios of mean fold change in induction of top 25 genes and
repression of top 25 genes by Org 214007-0 versus prednisolone
(see Figure S2). Expression of FKBP51, DUSP1 and GILZ was
confirmed by Q-PCR according to the same procedure as
described for the HepG2 cells. In this case THP1 cells were
stimulated with 40 ng/ml IFNc and 60 ng/ml TNFa and a whole
dose range of prednisolone and Org 214007-0 was tested.
Expression of FKBP51, MCP-1, IL-6 and IL-8 protein was
measured by specific AlphaLISAs (PerkingElmer; #AL244C
[MCP-1], #AL223C [IL-6] and #AL224C [IL-8]) according to
the manufacturer manual. For the FKBP51-specific AlphaLISA
anti-FKBP51 Mab (Abnova, Cat H0002289-M01) and Goat anti-
IgG FKBP51 polyclonal (Santa Cruz Biotechnology, Cat sc-
11514) were used and the same procedure was followed as for the
cytokine-specific AlphaLISAs (more detailed information in
Supportive Information) (SI text).
ChIP-Seq analysis
From the THP-1 samples that were used for gene expression
analysis after 6 hours, samples were drawn after 1 hour and used
for ChIP–Seq analysis at Genpathway (Carlsbad, CA). For
precipitation of genomic DNA regions antibody against GR
(Santa Cruz sc-8992) was used. Details are provided in SI text.
The obtained amplified DNA libraries were sent to Illumina
Sequencing Services (San Diego, CA) for sequencing on a Genome
Analyzer II. Sequence files were analyzed with the Genomatix
Genome Analyzer Workbench from Genomatix (Genomatix
Software GmbH, Munich). Sequences were clustered using default
parameter settings and aligned against the human genome version
GRCh37/hg19. Clusters were merged using the Replicate
Analysis module from the Workbench package (more detailed
information in SI text).
Human whole blood LPS- or PMA/anti-CD28-induced
cytokine release
Peripheral blood from healthy volunteers was collected into
lithium heparinised tubes, diluted with RPMI 1640 medium
(without phenol red) (Gibco BRL) and used within 3 hours after
collection. Diluted blood (final dilution 5x) was pre-incubated in
cell culture 96-wells flat-bottom plates (Nunc) together with
compound for 1 hour and further incubated with 1 mg/ml
Lipopolysaccharide (E. coli serotype 0111:B4, Sigma) or 100 ng/
ml phorbol 12-myristate 13-acetate (PMA, Sigma)/100 ng/ml
mouse anti-human CD28 antibody (Sanquin, The Netherlands)
for 24 hours in an incubator at 37uC, 6% CO2 and 95%
humidity. Hereafter, supernatant was carefully collected and tested
at the most optimal dilution (predetermined by a titration study on
control samples) in a human TNFa-specific ELISA (for the LPS
stimulated samples) or in a human IL-5-specific or human G-CSF-
specific ELISA (for the PMA/anti-CD28 stimulated samples)
(Duoset, R&D systems USA).
Animals
All animal procedures and experiments received approval by
the Ethics Committee on Animal Experiments of the University
Medical Center Groningen or the Ethics Committee on Animals
Experiments of MSD Oss and were according to the recognized
guidelines. Female Balb/c mice (Charles River, Sulzfeld, Ger-
many), male C57BL/6J OlaHsd (Harlan, Zeist, the Netherlands)
and male DBA/1J/BOM mice (Bomholtgard, Ry, Denmark) were
group-housed under controlled conditions with a constant tem-
perature (19–21uC), a 12-h light/dark cycle and ad libitum access to
Org 214007-0, a SGRM with Improved TI
PLOS ONE | www.plosone.org 12 November 2012 | Volume 7 | Issue 11 | e48385
water and standard laboratory chow pellets. For MIDA analysis,
C57Bl6 mice were equipped with a permanent right jugular vein
catheter afterwhich mice were allowed to recover.
Acute inflammation mouse models
For both the LPS-induced TNFa as well as the anti-CD3
induced IL-2 model, female Balb/c mice of 8–12 week old were
used. Mice were treated orally with 0.2 ml compound or vehicle
(water/mannitol (5%) with 5% DMSO/5% chremophore for the
LPS model or with 0.5% gelatine for the anti-CD3 model). One
hour after oral treatment animals were challenged i.p. with 0.2 ml
of either 20 mg/mouse LPS (Sigma, E. coli serotype 055:B5) or
5 mg/mouse hamster anti-CD3 monoclonal (BD Biosciences
Pharmingen, art. nr. 553057, clone 145-2C11). Ninety minutes
after LPS injection or 3 hours after anti-CD3 challenge, blood
samples were collected and serum levels of TNFa or IL-2 were
determined via specific ELISAs (BD Biosciences Pharmingen, San
Diego, CA, USA). In the experiment that included treatment with
RU486 to block GR, mice were dosed subcutaneously with
50 mg/kg RU486 30 minutes before the oral compound dosing.
ED50 and % efficacy (maximal percentage inhibition of TNFa or
IL-2 release) are determined using a 3 parameter sigmoidal curve
calculation. Statistical analysis of the results was performed using
an one-way ANOVA (log) test.
Mouse CIA model
The experiment was essentially performed as described pre-
viously [50]. At day 0 mice were immunized at the base of the tail
with 100 mg bovine type II collagen (UMC Nijmegen, The
Netherlands) in Complete Freund’s Adjuvant (CFA, Difco)
enriched with 2 mg/ml Mycobacterium tuberculosis H37RA (Difco).
At day 21 mice were boosted by an i.p. injection of 100 mg bovine
type II collagen dissolved in saline. After disease onset, mice with
an arthritis score ranging from 0.25 to 1.25 were divided into
matched groups (n = 12). Animals were orally treated once daily
with vehicle (0.5% gelatin/5% mannitol in water) or compound
for 21 to 23 days. The clinical severity of arthritis (arthritis score)
was graded and scored as described [51]. To assess the effects of
treatments, the area under the curve (AUC) of arthritis score
(subtracting baseline AUC of arthritis score on day 0) was used.
One day after the final treatment animals were sacrificed and the
knee and ankle joints were imaged using a Faxitron X-ray, Modl
MX-20 digital imaging system and analysed using Specimen
(Version 2.0.1). The bone destruction was scored on a scale of 0–5
as described previously [51]. The cumulative scores of 2 joints
(right ankle and knee) were used as radiological scores. From
H&H-stained sections, articular cartilage destruction and in-
flammatory infiltrate in the right knee joint were scored on a scale
of 0–3. The whole study was carried out in a blinded fashion.
Statistical analysis was performed using one-way ANOVA.
Micro array on muscle tissue mRNA from mice
Two and a half hours after the final treatment animals were
sacrificed and samples were collected from the thigh muscle
(musculus tensor fasciae latae and musculus rectus femoris). Samples were
stored immediately at 280uC and send to Covance (Princeton,
New Jersey) for RNA extraction and subsequent analysis of gene
expression on the Mouse Genome 430A 2.0 array. For statistical
analysis, the. CEL files obtained after hybridization were analyzed
with the R (www.r-project.org) and the BioConductor software
package (www.bioconductor.org) as described previously [36].
Normalization was done using gcrma. Building of the experimen-
tal design and calculation of the ratios was done with the limma
package. Differentially expressed probe sets were selected on basis
of the fold change and the adjusted p-value (Benjamini-Hochberg
correction). Multivariate data analysis and clustering was done
with standard methods in the R software package (www.r-project.
org). A therapeutic index for Org 214007-0 was calculated in the
same way as was described for the THP-1 microarray data.
Mouse fasting glucose and MIDA model for liver glucose
metabolism
For fasting blood glucose levels, male C57Bl/6J OlaHSD mice
(n = 8 per group, ,25 g) were treated daily by oral gavage for
28 days with either prednisolone (0.5 or 10 mg/kg/day), an
equipotent dose of Org 214007-0 (0.17 or 1.5 mg/kg/day), vehicle
(0.5% gelatin/5% mannitol in water) or no treatment as a stress
control. Eighteen hours after the last oral treatment and 9 hours
after start of starvation, blood samples were taken from the tail
vein and directly used for glucose measurements using ‘‘One touch
Ultra’’ glucose meter from Lifescan EuroFlash (Lifescan Benelux
Beerse, Belgium). The mouse MIDA study was performed as
described previously by van Dijk et al. [43,52]. Briefly, in-
dividually housed C57Bl/6J OlaHSD mice (n = 8) were treated
orally with prednisolone (10 mg/kg/day), Org 214007-0 (1.5 mg/
kg/day) or vehicle (0.5% gelatin/5% mannitol in water) daily for
7 days. On the third day, mice were cannulated in the right
jugular vein. After 7 days of treatment, mice were placed in small
Plexiglas cages, which allowed collection of blood samples
frequently in freely moving mice. Twenty four hours after the
final dose and after a 9 hours starving period, a tail vein blood
sample was used for a glucose measurement after which mice were
shortly anesthetized to attach the infusion lines before the
experiment. Filter paper was placed under the wired floor cages
to collect urine samples and replaced hourly. Mice received an
infusion of a sterilized aqueous solution containing [U-13C]glucose
(13 mmol/ml), [2-13C]glycerol (160 mmol/ml), [1-2H]galactose
(33 mmol/ml) and paracetamol (1 mg/ml) at a rate of 0.54 ml/
hr for 6 hours. During the experiment blood glucose was
measured and blood spots for GCMS measurements were
collected from tail tips just before the start of the infusion and at
hourly intervals. Blood spots and urine filter papers were air-dried
and stored at room temperature until analysis. Glucose and
paracetamol-glucuronic acid (Par-GLcUa) were extracted from
blood spot and urine filter papers, respectively, derivatised, and
measured by GC-MS, essentially as described previously [43,52].
The fractional isotopomer distribution according to GC-MS was
corrected for fractional distribution due to the natural abundance
of 13C by multiple linear regression to obtain the excess mole
fraction of mass isotopomers M0-M6 due to incorporation of
infused labeled carbohydrates. From isotope dilution and infusion
rates, the flux rates of the following metabolic pathways could be
calculated: 1) de novo synthesis of G6P, 2) glucokinase, 3) glucose-6-
phosphatase, 4) glycogenolysis, and 5) glycogen synthesis. The
method of calculation was performed as described before
[43,52,53].
Supporting Information
Figure S1 Org 214007-0 partially induces expression of
GC-regulated genes in the human HepG2 cell line.
HepG2 cells were incubated with either vehicle, Org 214007-
0 or prednisolone for 6 hours. RNA was isolated and expression of
tyrosine aminotransferase (TAT) and glucose 6-phosphatase
(G6Pase) was quantified by Q-PCR, expressed as fold induction
in comparison to vehicle treated cells.
(TIF)
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Figure S2 Calculation of the relative therapeutic index
(TI) based on micro array data. For the two sets of top 25
genes either induced or repressed with the highest change fold by
prednisolone and Org 214007-0 in THP1 cells (shown in Figure 4A
and 4B respectively), a mean fold change (FC) was calculated
(shown on the Y-axis as a 2log ratio compared to control, the
expression of the genes without compound). MeanFCI is the mean
fold change of expression of genes induced by prednisolone (Pred)
or Org 214007-0 (Org). MeanFCR is the mean fold change of
expression of genes repressed by prednisolone (Pred) or Org
214007-0 (Org). The ratio between induction and repression for
both compounds can be calculated as meanFCI – meanFCR. For
Org 214007-0 this is 1.21–0.71 = 0.50. For prednisolone this is
3.61–1.76 = 1.84. The difference is thus 1.84–0.50 = 1.34. This
corresponds to a mean difference in fold change of 2ˆ1.34 = 2.53
fold change, the relative therapeutic index (TI) of Org 214007-0.
The percentage maximal efficacy of induction of genes and
repression of genes by Org 214007-0, in comparison to
prednisolone (both set at 100%), in this setting becomes re-
spectively: 2ˆ1.21/2ˆ3.61 * 100% = 18.9% and 2ˆ0.71/2ˆ1.76 *
100% = 48.3%.
(TIF)
Figure S3 Org 214007-0 behaves as a partial agonist in
THP1 cells. In comparison to prednisolone, Org 214007-
0 behaves as a partial agonist in THP1 cells with a stronger
partiality on induction of genes (FKBP51, DUSP1 and GILZ) than
on the repression of genes (MCP-1, IL-8 and IL-6) under
inflammatory conditions. Induction of FKBP51, DUSP1 and
GILZ were evaluated by Q-PCR on mRNA isolated from THP1
cells, incubated for 6 hours with compound. Repression of MCP-
1, IL-8 and IL-6 was measured on THP1 cell supernatant
collected 6 hours after incubation with compound and stimulus.
(TIF)
Figure S4 The anti-inflammatory effect of Org 214007-
0 is mediated through the glucocorticoid receptor. Mice
were treated p.o. either with vehicle, Org 214007-0 (0.5, 1, 2 or
4 mg/kg) in a co-treatment schedule with either a vehicle or
RU486 (50 mg/kg) s.c. injection. TNFa was quantified 1.5 h after
LPS challenge. Data is represented as mean 6 SEM. An one way
ANOVA was used for statistical analysis. An asterix (*) represents
significant difference from vehicle (p,0.05).
(TIF)
Figure S5 Org 214007-0 reduces all parameters scored
by histological examination of the knee joints of CIA
mice. At the end of the CIA study (after 3 weeks of daily oral
treatment with equipotent dosages of prednisolone and Org
214007-0) knee joints were fixed in 4%-buffered formaldehyde
and decalcified. After decalcification the joints were washed,
dehydrated and embedded in paraffin. Serial sections of at least
7 mm were stained by Hematoxylin-Eosin (for cellular infiltration
and exudate formation into the joint space and bone apposition),
or by toluindin blue staining (for proteoglycan depletion and
cartilage and/or bone destruction of the joint). Org 214007-0, at
0.5 and 1.5 mg/kg, significantly reduced the formation of new
bone (bone apposition), the infiltration of inflammatory cells in the
joint cavity (exudate) or joint tissue (infiltration), cartilage
destruction and proteoglycan depletion in the articular cartilage
(PG depletion). Each of the histological parameters is scored at
a scale of 0–3. Mean score of each group of mice (n = 12) is
indicated (6 SEM). ** = significantly different from vehicle
(p,0.01; ANOVA-test).
(TIF)
Figure S6 Org 214007-0, at a dose that is equi-effica-
cious to prednisolone, induces less fasting glucose. Mice
(n = 8 per group) were treated p.o., once daily, for 7 days with
either vehicle (V), 10 mg/kg prednisolone (P) or 1.5 mg/kg Org
214007-0 (O). Blood glucose levels (mean 6 SEM) were measured
at day 8, after 9 hours of fasting. ** p,0.01: significantly different
(Student’s t-test) from vehicle-treated group; # p,0.05: signifi-
cantly different (Student’s t-test) from prednisolone-treated group.
(TIF)
Text S1 More detailed information on Material and Methods
and Table S1, Table S2, Table S3 and Table S4.
(DOC)
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